SUPN – supernus pharmaceuticals, inc. (US:NASDAQ)

News

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $57.00 price target on the stock.
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference [Yahoo! Finance]
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
Supernus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com